Last updated: March 2, 2026
What is Phenyl Aminosalicylic Acid?
Phenyl Aminosalicylic Acid (PAS) is an antibiotic primarily used for the treatment of tuberculosis (TB). It is a derivative of para-aminosalicylic acid (PAS), a second-line anti-tubercular agent. Its usage has declined with the rise of newer drugs but remains relevant for multidrug-resistant TB (MDR-TB) cases.
Current Market Landscape
Therapeutic Use and Market Penetration
PAS is indicated mainly for tuberculosis therapy, especially in cases resistant to first-line drugs like isoniazid and rifampicin. The global TB burden remains significant, with approximately 10 million cases reported annually (WHO, 2022[1]). MDR-TB accounts for approximately 3.5% of new TB cases. The need for second-line therapies sustains demand for PAS in specific niches.
Production and Supply Chain
Major pharmaceutical companies in China, India, and Russia manufacture PAS. Limited production volume and age of manufacturing assets restrict supply elasticities. International supply chains face disruption risks due to geopolitical tensions and regulatory bottlenecks.
Market Players and Patent Status
Current patent protections for PAS have mostly expired, categorizing it as a generic drug. Several manufacturers produce it at significantly low costs, limiting profit margins but ensuring steady market presence in endemic regions.
Regulatory and Approval Trends
PAS remains an essential medicine listed by WHO and is included in multiple national TB treatment guidelines. Regulatory approvals are stable; however, the drug's usage could decline with the development of newer therapies.
Market Drivers
- Rising MDR-TB cases: MDR-TB increases the use of second-line agents like PAS.
- Global TB control initiatives: WHO and Gavi funding support access to second-line drugs in low-income countries.
- Limited new drug pipeline: Scarcity of novel agents in the second-line TB space sustains demand for existing drugs like PAS.
Market Constraints
- Declining use in first-line therapy: Advances in TB treatment favor newer agents, pushing PAS toward niche markets.
- Safety profile concerns: PAS's side effects limit its attractiveness compared to newer drugs.
- Price competition: Generic manufacturers dominate, keeping prices low and margins thin.
Financial Trajectory
Revenue Trends
Global PAS revenue approximates $50-100 million annually, with key sales concentrated in Asia and Africa. Growth rates have been flat or slightly declining at approximately 1-2% annually over the past five years (IQVIA, 2022[2]).
Cost Structure
Manufacturing costs are low, estimated at around $0.10 to $0.50 per tablet, mainly for active ingredient synthesis and formulation. R&D expenses are minimal, as the drug's patent has expired.
Future Revenue Potential
- Expect stable revenues in MDR-TB markets.
- Potential growth driven by increasing MDR-TB prevalence, particularly in India and China.
- Declining use in new TB cases may hinder overall sales growth.
Investment Considerations
Limited innovation and reliance on a narrow niche restrict profitability. Companies with existing manufacturing assets could sustain minimal revenues without major capital investment. Novel formulations or combination therapies might unlock market expansion but are unlikely to alter the trajectory drastically.
Comparative Analysis
| Aspect |
Phenyl Aminosalicylic Acid |
Newer Second-line Drugs |
| Patent Status |
Expired, generic |
Mostly patent-protected |
| Cost per Unit |
$0.10 - $0.50 |
$50 - $200 per treatment course |
| Market Growth (5-year CAGR) |
1-2% decline |
Variable, some double-digit growth in MDR-TB markets |
| Therapeutic Profile |
Effective but older, safety concerns |
Better tolerated, newer formulations |
Strategic Outlook
The market for PAS remains steady due to its role in MDR-TB treatment. Long-term growth prospects depend on the global burden of resistance, regulatory decisions, and advances in alternative therapies. Developing combination formulations could enhance value but face regulatory and clinical hurdles.
Key Takeaways
- Demand for PAS is tied to MDR-TB prevalence and will remain consistent in endemic regions.
- Market revenues are modest, with minimal future growth expected.
- Competition from newer agents limits expansion; price competition among generics sustains low margins.
- Supply chain stability and regulatory approval are prospects for risk management.
- Innovation is unlikely to significantly alter the current market trajectory.
FAQs
1. Will PAS see increased demand in the future?
Demand correlates with MDR-TB rates. Rising MDR-TB could sustain or slightly boost demand, especially in China, India, and Russia.
2. Are there new formulations or combination therapies involving PAS?
Research exists into combination drugs with PAS, but regulatory and clinical hurdles slow adoption.
3. How does the safety profile affect PAS's market?
Safety concerns limit use, especially compared to newer drugs with fewer side effects. Its niche use in MDR cases keeps it relevant.
4. What factors threaten the stability of PAS supply?
Manufacturing reliance on limited facilities and geopolitical risks could disrupt supply.
5. Is there room for profit growth with PAS?
Limited due to patent expiry, generic competition, and minimal innovation. Niche markets sustain revenue but not significant growth.
References
[1] World Health Organization. (2022). Global Tuberculosis Report. WHO.
[2] IQVIA. (2022). Market Intelligence Report: Second-line Anti-tuberculosis Drugs. IQVIA.
